UK drugmaker Argenta Discovery has started a Phase II trial with ADC4022 for the treatment of chronic obstructive pulmonary disease (COPD) and steroid-insensitive asthma.

The multicenter, randomized, double-blind, placebo-controlled study will evaluate the effect of inhaled ADC4022 and an inhaled corticosteroid on markers of inflammation and pulmonary function over a four-week period, according to Argenta.

Argenta has several candidates in the pipeline, including one in preclinical studies being developed with India’s Dr. Reddy’s Laboratories.